Bob is a veteran operating executive and transaction advisor specializing in Oncology, CNS, and Diagnostics. He has led and advised on $12.5B+ of M&A, licensing, and portfolio transactions, bringing the “clinical value + ability-to-compete” diligence that helps sponsors and strategics underwrite conviction and close. He is known for connecting scientific promise to investable commercial reality - stress-testing differentiation, adoption drivers, and the practical path to scale. Today, as Principal at Strategic Value Inflections (SVI) LLC, Bob advises private equity firms and management teams on “deal-to-value” execution, from diligence through value creation planning. His approach is grounded in hands-on leadership of global commercial organizations, where he partnered closely with physicians to validate real-world clinical utility and structured complex market access and contracting strategies with integrated delivery networks and other key stakeholders. He previously held senior leadership roles in strategy and portfolio management at Mallinckrodt Pharmaceuticals, leading licensing, R&D, and portfolio initiatives that advanced and scaled high-potential oncology programs. Bob brings a buyer’s perspective, helping founders de-risk regulatory and payer pathways, sharpen the value story, and prepare for the scrutiny of big pharma acquirers and institutional capital. Beyond work, Bob is passionate about applying technology for human impact and has recently explored the intersection of AI and wellness through a personalized mental health support agent built for a loved one.
